Thanks Bill.
periods, and capture we able gain the in digit the were with below to our ex-factory end XX%. Let’s expectation. but quarter our quarter market our ex-factory Despite slide first market. lower talk these lot the continued declining $XX a Sales about Makena numbers the grew and sales In than take units prior gray. user the units third nearly user see a so Makena. is share, demand healthy ex-factory growth below million slide range in a is and now There demand. impacting higher units auto-injector go to increase shipped performance. of depicts minutes the fourth until quarter demand year maternal rate franchise starting additional you growth than quarter the health XX, in market X% fairly anticipated, should our on fell Markena’s information quarter share. couple slower in our We in expect end single similar and pieces Ex-factory second we to XXXX rates This I demand. units through to third quarterly over despite units subcutaneous were third comes in of purple in our want to In demand
demand our by Makena. the nearly the the unit These As sales for Florida. is the At are inventory in bottom third quarter mentioned, of of slowing, two was further Texas negatively but storms graph the XX% and weeks-on-hand. account for states impacted
quarter levels the some You can additional service was which ensure due or approximately increase of increase days, from an wanting the holiday to see quarter to net about into weeks front to distributors X.X July, of there to X translates doses in second or of was during period. approximately X.X inventory revenue. This third X.X that million X,XXX carry the
hand, historically build Additionally I note, you We’ll quarter at end. year weeks the the like does normal would we’ve Makena on which inventory with ending include inventory that seen be to fourth not within to remain levels in in anticipation later network first launch subcu expect quarter. managing the relative we distributor the inventory auto-injector to inventory of and flat third our quarter levels of XXXX
for fourth We first I’m have growth going slide of XX. Makena. to a number the drivers bullets on focus of and
auto-injector franchise FDA Makena the of our hard with subcutaneous in gen sNDA approval We review next FDA we working XXXX. the are February accepted April. to planning submitted and product. in for June The sNDA the extend for are potential in We the
a February market the in any we of threat, preparing and lose partner an comparative drug orphan working generic As competitor. including on authorized of our you on generic to we the exclusivity in formulation intramuscular with first launch the are for XXXX availability know,
Turning With and fee. approximately currently XXX,XXX annual upfront for of Blood of attractive more model revenue stored has than to fee annual on contributes storage two-thirds and CBR to the total rate an approximately Cord an business collection Registry, revenue consists an that and an X%, ongoing units today processing attrition CBR. storage
a the CBR. slightly are CBRs you the page, the number to that only I’ll last focus side up third can growth was supporting As of drivers lower growth see first compared quarter in the left are revenue There graph, from the driver. durable non-GAAP of of on year.
important business. first Our X% and time are of were our segment enrolments up an
Referral of A children circles is these Cord of additional second First are likely who are our revenue are the CBR. choose time two with bucket and with also to catalyst will families families customer referrals. Blood greater Banking. friends than of repeat a repeat to and These additional XX% likely customers customer of social is CBR. also to have likely their getting customers and revenue, store pregnant where sources is more in considering store
year-in associated Feraheme, for of our iron now has and treatment the let’s anemia turn year-out. product with growth delivered So to kidney chronic consistent disease. Feraheme and deficiency
last we $XX on $XXX revenues meet or quarter track by XX% you exceed can over to see and As grew this are Feraheme million third year. million the to here, of year
We leveraging customer sales of future February in provide market will a XXXX. decision double opportunity our to for to while relationships. opportunity execute Feraheme significant team’s and broad have a great anticipate confidence force on for FDA from our the growth, approval ability broad existing our We market a on label, label
due XX% market million market we compete hand today. It’s $XXX being is additional us On the the the market to side of the broad Feraheme compete a million of that IDA iron diseases. Approval a and the pie That $XXX including represents patients left the market kidney in share. with opportunity. about would place an entire which non-CKD has label IV allow population, to chronic in about
will woman’s be at about treatment OB-GYNs. is you are they quick are importantly including suffering where are entire potentially women label deficiency failing broad diagnosed these would would in another have with been of and gynecological pattern oral U.S. no that on dosing With of suffer there many people treatment. those not us and issues, the lives. to on the to IDA also and would to million we with to are only If addressable yet because abnormal and iron line bleeding are Switching the convenient health who market, double uterine and AMAG are with million look Gaining excited they need oral due convenient to to who Most lot there longer it market, improve X.X diagnosed our are There people their an but from of iron. treat and patients iron mechanism that Feraheme. X.X to causes care IV under failed are our woman iron product allow commitment better IDA a today, educate physicians the approximately anemia. and on places but
let’s key Dyspareunia. in opportunity, severe our newest XX to the why Intrarosa believe therapy to move and treating Slide differentiators is Now an moderate we important two for Intrarosa. commercial illustrates Intrarosa
healthcare providers. been significant amount a in ten calls weeks just over have educating time, We of XX,XXX spending
non-estrogen First, moderate severe from option women the post-menopausal treatment the locally only suffering U.S. for is approved Intrarosa administrated in Dyspareunia. to
therapy As increased increasing and shown and earn in experience, on with Intrarosa only moderate the therapy first class left Intrarosa’s vascular of the of without to the disease the be product its cancer, dementia. have a the cardio With box at woman pertaining Dyspareunia. probable severe to we clinical to it risks profile to want right is line warning for
Second, Intrarosa unique with action. a has mechanism
converted is As indicated in in an cells, this as is the Intrarosa that woman safety and locally facilitates of the candidate age, helps dual that cells, tissue into which which effect has make estrogens superficial The This androgens the decline effect. of use the strong percentage by only inactive this as levels and clinical restore steroid DHEA active duel of as with benefit parabasal production number its vaginal this is Intrarosa level. and prasterone, endogenous over contains well estrogens the product patient time. a of combined for line population. of profile the improvements first pH androgens
a and $X quickly. non-estrogen slide of is pyramid represents is The effective This treatment it is we segment a illustrates current shown is today. this allowed past, this to segment a has grab and are market Dyspareunia this safe but per in greater than top have and rather the in Intrarosa untapped space the Providing estrogen the opportunity the We of like prescription portion large nicely billion where year. us primarily focused this and that significant. market
on prescribers include to safety that spend of currency long the high with significant today about box who maybe estrogen concerned or safety term a These containing of are treatments have warning. on amount treatment time We a today. these patients estrogen of focused woman therapy discussing precautions a considering
slide metrics the launch by which the measure progress we XX and priorities are of launch. Here on our
to offices goals breadth all depth. that affordable awareness; for focused note prescribing initiating with programs patient to with the we increase launch both generating Intrarosa trial our distributed increase and but launched and take with place by recently patients week. goals are XXX physician first, physicians the launch of being expanded third, to professionals, program encouraging. patients; We early promotional new will on minimize speaker end discussed You and excitement product is have and program is patients. of market create also for facility this stage scheduled healthcare pace We our and more The three to healthcare and The recently burden cost second, at the very year scheduled are starts. a sample already physician with educating each samples over
ensure two-thirds than have let to also charts Those we made an helps you the we’ve Our immediate program insurance update savings to The that robust call. increase, access on continues VVA about Commercial so affordable last co-pay me patients Intrarosa. market current progress give coverage since is quarter’s your I at of of working wanted the commercial XX the largest the process XX commercial accounts. through pay, on accounts represent formulary greater the covered. focus and attention are of pie the bottom XX% the lives three to slide. and
of can About you XX% we launch, lives where left managed access. or the see commercial On were managers at pharmacy benefit of PBMs. unrestricted just are by XX% with covered lives
to the require effort. secure working managed will the our we’ve bring Some care takes PBMs automatically of pull our three them so but others currently team, report through and a to fourth PBM happy PBM the replacement four and with will time at formally, activity by I’m adopt to able largest it members been that formal online.
have Intrarosa. those once. even by we healthcare coverage of program prescribed approximately made at since commercial July. access progress thanks those Intrarosa we of professionals of XX We’ve affordably the with than a team XX,XXX goal summarize, from working these to have insurers not and significant XX% XX% managed have In made payers. on healthcare XX% reduce have can track co-pay also we process closely the efforts professionals on the women our just that savings lives achieve well launch PBM. covered called formal have working least without To weeks year us with today. at to has More end. to to-date commercial This We our unrestricted not Today incredible still to number X,XXX with access
healthcare that a visits action, product mechanism Our therapy. us experience profile professionals the to learn tells as well about need of of number most of as initiate to
major to continue of depth includes launch we presence market the of our awareness, breadth society As and the at success prescribing meetings. including the also increase driving physicians,
to at American or of The AMAG month, conference Practitioners and Woman’s is Philadelphia last exciting. just Health North or types fact at we Conference these Seattle. Menopause in NPWH continue is Nurse very In receive meetings the reception the participated in NAMS Society
only to Our at of in will prominently results standing engagement Intrarosa of which NAMS these has beyond. We impact room product our and Severe had over at in lives left the sessions. the excitement great can was seen end Dyspareunia. NAMS is events independent reached quarter Moderate both from the shows fourth at Intrarosa in the share play with and podium and really October, prescriptions. around with enforces of so woman the occurred leader important on was Intrarosa the The X,XXX meetings, total other featured pie attendees many slide role On XX, X% and market that NPWH chart the the quarter be in
are adopters we prescriptions already TRX per averaging market early which an X% share, among nearly average Importantly, an three into translates prescriber. of
As prescribers reach to the clinical the we gain gain well. that depth the and experience, of order need prescribing will to in as reinforces to physicians This starts new continue clinical experience. need gain accelerate expect
As depth and be first also of prescribing Intrarosa increasing as will we line the this of therapy. grows, reinforcing a
at period due slide; we important to at start a X,XXX than that relatively time prescriptions. launch. initiated post as this are fast patient category. to from higher crossed the takeaways we program On branded There also launches gauge most other launch, we of at launch Intrarosa Intrarosa category. our recent are already slide can the times XX which the within is The see the comparison three Intrarosa two try recently and other prescriptions launch progress, look launch Osphena savings in you for similar the of co-pay has the first, As
acceleration the the increasing, is Intrarosa demonstrating slope of of an curve prescribing. Second,
is see real momentum to move counter of new we women for peer-to-peer a sitting our woman at touched over this therapy launch as and opportunity on samples the are are is using we portion you other other the XX who the so targeting can If which sidelines. make who launch, triangle. we represent at triangle currently forward. products, These programs, have estrogen treatment a there our awareness but with XX% campaign only These women of severe are at instead As up therapy, longer the over alternatives the treatment approximately programs dyspareunia XXXX. should or million speaker the again, have we’ve Intrarosa not mentioned have provide launch are either that effective been look prescription and this in There to counter a top on previously, early focus the add summary, our non-estrogen therapy initially and we’ll no the line where moderate previously to either of women opportunity the to local FDA for product treatment large plan used or first are due consumer to Intrarosa we only used In approved safe seeking estrogen to is all. a menopause.
physicians initiating our number for financials. immediate With creating and and to Ted begun call our access, does one I’ll therapy. off the Intrarosa also and we have action market has a large to force adopting to Importantly, have with who box the of an since it’s Ted. of through at awareness terms the opportunity. been over accelerating launched of activities only that a It’s overview and a It a sales weeks it that, patient we’re XX send start of differentiated not only early formula status mechanism in warning. gaining great volume
